Navigation Links
60 Degrees Pharmaceuticals to Begin Phase II Clinical Trials in Dengue Fever Patients
Date:8/20/2015

WASHINGTON, Aug. 20, 2015 /PRNewswire/ -- 60 Degrees Pharmaceuticals, (60P), a company focused on development of therapeutics for tropical diseases, and Singapore General Hospital (SGH) announced today that the Hospital has received a grant from Singapore's National Medical Research Council to support a Phase II clinical trial among dengue fever patients.

Dengue fever, a painful, debilitating and potentially deadly mosquito-borne viral disease, infects an estimated 400 million people worldwide each year, causing 500,000 hospitalizations and creating a $12 billion annual burden. Instances of dengue, which cause flu-like symptoms and can develop into lethal severe dengue, have increased 30 fold over the past few decades.

Once believed to be only a "tropical" disease, there have been outbreaks in southern U.S. including Florida, as well as in France, Portugal and other European countries, which experts believe may expand in North America and Europe. In addition, scientists have discovered a type of dengue-carrying mosquito which can live in colder climates, meaning cases of dengue observed in the U.S. and Europe may increase substantially.

There are currently no FDA-approved vaccines or antiviral drugs for dengue virus infection and treatment has been limited to supportive and symptomatic treatment.

60P and SGH will evaluate the safety and effectiveness of an antiviral, Celgosivir, and a disease- modifying agent, Modipafant, in the treatment of dengue.  Earlier animal studies suggest these drugs could prove effective in dengue fever patients. SGH and Duke-NUS Graduate Medical School previously evaluated the efficacy of Celgosivir in dengue patients, establishing its safety.

60P and SGH have received approval from the relevant authority in Singapore and Institutional Review Board for the study, which is scheduled to start March 2016.                        

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, a privately-held company founded in 2010 with a mission to develop small molecule therapeutics for tropical diseases, is focused on development of products with dual use application in the travel medicine market and tropical countries.  The company's development portfolio includes three repositioned dengue therapeutics and an antimalarial drug that has completed Phase III trials.

After executing an exclusive option deal and research agreement with the United States Army in 2014, 60P is preparing for the commercial launch of Tafenoquine for traveler's malaria prophylaxis. Due to its unique mode of action, Tafenoquine also has potential utility for community prophylaxis in malaria-endemic countries in combination with existing control measures. 60P's mission is supported through substantial in kind funding from the United States Department of Defense and other agencies of the U.S. government.  

60 Degrees Pharmaceuticals is headquartered in Washington DC, with a subsidiary in Australia.                                                                                    

Further information is available on the Company's website, www.60degreespharma.com.  

For Further Information Contact:
Roseann Rosetta, Director, Account Management
Integrated Marketing Services
rrosetta@imsworld.com  
609-683-9055 x247

Goeff Dow, CEO, 60 Degrees Pharmaceuticals       
geoffdow@60degreespharma.com

 


'/>"/>
SOURCE 60 Degrees Pharmaceuticals
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Pharmaceuticals To Acquire Sprout Pharmaceuticals
2. DelMar Pharmaceuticals Completes $2.6 Million Registered Direct Offering
3. Dipexium Pharmaceuticals Surpasses Treatment of 50% of Subjects in Pivotal Phase 3 Clinical Trial
4. Rock Creek Pharmaceuticals to Present at the Annual BioPharm America International Partnering Conference
5. Hi-Tech Pharmaceuticals Acquires LG Sciences Adding to its Premium Line Up of Sports Nutrition Brands
6. DelMar Pharmaceuticals Receives Additional Non-Dilutive Funding from NRC-IRAP to Support Expanded Research Program with Lead Product Candidate VAL-083
7. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Fiduciary Duty by the Board of Ariad Pharmaceuticals Inc. -- ARIA
8. Rock Creek Pharmaceuticals to Present at the 17th Annual Rodman & Renshaw Global Investment Conference
9. CASI Pharmaceuticals Reports Second Quarter 2015 Financial Results
10. TWi Pharmaceuticals Announces 2Q 2015 Financial Results and EPS for 2Q of NT$0.69
11. Cantex Pharmaceuticals Enhances Executive Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2020)... PHOENIX (PRWEB) , ... August 31, 2020 , ... ... Mobile Sanitizing and Disinfecting - a broad-spectrum sanitization, disinfection and deodorization provider ... company will offer door-to-door sanitizing and disinfecting services for businesses and residents throughout ...
(Date:8/28/2020)... ... August 28, 2020 , ... ... aesthetic beauty, bringing a unique perspective and approach. Armed with her qualifications from ... out to share her knowledge of the human body with the nation and ...
(Date:8/27/2020)... (PRWEB) , ... August 27, 2020 , ... Bleep LLC, ... player and sleep apnea patient, is the company’s new spokesperson. , “In my line ... field. So, when I found the Bleep DreamPort it was a Bleeping no brainer ...
Breaking Medicine Technology:
(Date:8/31/2020)... (PRWEB) , ... August 31, 2020 , ... ... recently donated 1,400 N95 face masks to medical first responders across the United ... to make donations of personal protective equipment (PPE) medical centers , ...
(Date:8/31/2020)... ... August 31, 2020 , ... ... higher-learning opportunities through high-quality, career-relevant, and affordable online education – is proud to ... , Among the first of its kind in the nation, the 60-credit ...
(Date:8/31/2020)... (PRWEB) , ... August 31, 2020 , ... A Cure for Covid-19 “PTS” with Mediation ... on the planet are in a state of panic, experiencing deep anxiety, immense stress, and ... now, a solution is timely when most people on the planet are experiencing a great ...
(Date:8/31/2020)... , ... August 31, 2020 , ... ... to improve outcomes for patients with advanced heart failure, today announced that the ... in the amount of $555,358 from the National Heart, Lung, and Blood Institute ...
(Date:8/28/2020)... , ... August 28, 2020 , ... ... system designed to help treat patients with respiratory conditions, including COVID-19, while reducing ... helium and oxygen, but it captures exhaled gas and scrubs it free of ...
Breaking Medicine News(10 mins):